

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

FIG. 1




Fig.2A Fig.2B Fig.2C





Fig.2D




Fig.2E

	230	240	250	260	270
humIgG1	PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV				
humIgG2	PAP - PVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYV				
humIgG3	PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYV				
humIgG4	PAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSEQEDPEVQFNWYV				
murIgG1	- - -TVPEVSSVFIFFPPKPKDVLITITLTPKVTCVVVDISKDDPEVQFSWFV				
murIgG2A	PAPNLLGGPSVFIFFPPKIKDVLMISSLPIVTCVVVDVSEDDPDVQISWFV				
murIgG2B	PAPNLEGGPSVFIFFPPNIKDVLMISSLTPKVTCVVVDVSEDDPDVQISWFV				
murIgG3	PPGNILGGPSVFIFFPPKPKDALMISLTPKVTCVVVDVSEDDPDVHVSWFV				

	280	290	300	310	320
humIgG1	DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP				
humIgG2	DGVEVHNAKTKPREEQFNSTFRVSVLTVVHQDWLNGKEYKCKVSNKGLP				
humIgG3	DGVEVHNAKTKPREEQFNSTFRVSVLTVLHQDWLNGKEYKCKVSNKALP				
humIgG4	DGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLP				
murIgG1	DDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDCLNGKEFKCRVNSAAFP				
murIgG2A	NNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLP				
murIgG2B	NNVEVHTAQTQTHREDYNSTIRVVSHPILQHQDWMSGKEFKCKVNNKDLP				
murIgG3	DNKEVHTAWTQPREAQYNSTFRVVSALPIQHQDWMRGKEFKCKVNNKALP				

	330	340	350	360	370
humIgG1	APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV D L				
humIgG2	APIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV				
humIgG3	APIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV				
humIgG4	SSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAV				
murIgG1	APIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITV				
murIgG2A	APIERTISKPKGSVRAPQVYVLPPEEEMTKKQVTLTCMVTDFFMPEDIYV				
murIgG2B	SPIERTISKPKGLVRAPQVYTLPPPAEQLSRKDVSLTCLVVGFNPGDISV				
murIgG3	APIERTISKPKGRAQTPQVYTIPPPREQMSKKKVSILTCLVTNFFSEAISV				

	380	390	400	410	420
humIgG1	EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSQSVMH				
humIgG2	EWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSQSVMH				
humIgG3	EWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFQSVMH				
humIgG4	EWZSNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSQSVMH				
murIgG1	EWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNQKSNWEAGNTFTCSVLH				
murIgG2A	EWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSQSVVH				
murIgG2B	EWTSNNGHTEENYKDTAPVLDSDGSYFIYSKLNMKTSKWEKTDSFSCNVRH				
murIgG3	EWERNGELEQDYKNTPPILSDSGTYFLYSKLTVDTDTSWLQGEIFTCSVVH				

	430	440
humIgG1	EALHNHYTQKSLSLSPGK	
humIgG2	EALHNHYTQKSLSLSPGK	
humIgG3	EALHNRFTQKSLSLSPGK	
humIgG4	EALHNHYTQKSLSLSPGK	
murIgG1	EGLHNHHTTEKSLSHSPGK	
murIgG2A	EGLHNHHTTKSFSRTPGK	
murIgG2B	EGLKNYYLKKKTISRSPGK	
murIgG3	EALHNHHTQKNLSRSPGK	

Figure 3





Fig. 5



HERCEPTIN®

OctHER2 1:2 / H:L




Fig. 6A

293 rhu MAb 4D5




Fig. 6B

vialled HERCEPTIN®





Fig. 6C

Fig. 7











Fig.9






Fig. 10A

Fig. 10B

Fig. 11 A-F




Fig. 11G




Fig. 11H

OctHER2 - 5hr

Multivesicular
Body




Fig. 11 I



Fig. 12A






Fig. 12E

Fig. 12B



HOP 92




Fig. 12C




Fig. 12D

Fig. 13A




Fig. 13C




Fig. 13B




Fig. 13D




Fig. 14




Fig. 15




Figure 16 shows the effect of various concentrations of the test substance on the response of the 3H3 octopus and 16E2 octopus cell lines. The graph plots the percentage of control response against the concentration of the test substance in ng/ml. The x-axis is a logarithmic scale ranging from 0.001 to 10⁵ ng/ml. The y-axis represents the percentage of control response, ranging from 40 to 110. The legend identifies six data series: 3H3 octopus (filled squares), 16E2 octopus 3.0A (open circles), 16E2 octopus 2.1 (open circles with a cross), 16E2 octopus 2.6 (open circles with a dot), 16E2 octopus 3.0B (filled circles), and 16E2 octopus 5.8 (open circles with a horizontal line). All series show a dose-dependent decrease in response, with the 3H3 octopus line generally showing the most potent effect at lower concentrations.

Fig. 16




Fig. 17A




Fig. 17B






Fig. 18 A






16E2 Octopus (anti-DR5) - 2 day






APO2L - 2 day

Fig. 18 B

Figure 18B shows the effect of 16E2 Octopus (anti-DR5) on the growth of various cancer cell lines. The graphs show the percentage growth of the cells over a 2-day period for different concentrations of the antibody. The cell lines are grouped into three categories: CNS Cancer, Melanoma, and Ovarian Cancer. Each category has a corresponding graph. The x-axis for all graphs is 'Log₁₀ of Sample Concentration (Vol. Dil.)' ranging from 0 to 2. The y-axis is 'Percentage Growth' ranging from -100 to 100. The legend for each graph indicates the cell lines and the concentration of 16E2 Octopus used.









16E2 Octopus (anti-DR5) - 2 day



APO2L - 2 day

Fig. 18 C


16E2 Octopus (anti-DR5) - 2 day




APO2L - 2 day

Fig. 19 A

Figure 19A shows the effect of 16E2 Octopus (anti-DR5) on the growth of various cancer cell lines. The graphs show percentage growth over time (0 to 6 days) for different cell lines and concentrations of the antibody. The y-axis represents Percentage Growth (0 to 100) and the x-axis represents Log₁₀ of Sample Concentration (Vol. Dil.) (0 to 3). The legend indicates the cell lines and the concentration of the antibody (Vol. Dil.).






16E2 Octopus (anti-DR5) - 6 day






APO2L - 6 day

Fig. 19 B






16E2 Octopus (anti-DR5) - 6 day






APO2L - 6 day

Fig. 19 C



16E2 Octopus (anti-DR5) - 6 day



APO2L - 6 day

16E2 Octopis (anti-DR5) is "2 day"

Panel/Cell Line	Time Zero	Ctrl	Mean Optical Densities			Log10 Concentration			Percent Growth			GI50	TCI	LC50			
			0.5	1.0	1.5	2.0	0.5	1.0	1.5	2.0							
Leukemia	CCR-CEM	0.081	0.557	0.526	0.491	0.457	0.299	0.125	94	86	79	46	9	2.74E+01	>1.00E+02	>1.00E+02	
	HL-60(TB)	0.487	1.935	1.821	1.927	1.486	0.843	0.561	92	93	69	25	5	1.64E+01	>1.00E+02	>1.00E+02	
	K-562	0.218	1.548	1.525	1.473	1.494	1.458	1.00	98	94	96	93	3	>1.00E+02	>1.00E+02	>1.00E+02	
	MOLT-4	0.235	1.046	0.976	0.908	0.890	0.888	0.874	92	83	81	63	65	>1.00E+02	>1.00E+02	>1.00E+02	
	NPM1-B226	0.335	1.302	1.067	1.009	0.947	0.937	0.959	76	70	61	62	79	>1.00E+02	>1.00E+02	>1.00E+02	
	SR	0.279	1.868	0.965	0.807	0.681	0.600	0.537	43	33	25	20	16	<1.00E+00	>1.00E+02	>1.00E+02	
Non-Small Cell Lung Cancer	A549/ATCC	0.212	1.132	1.155	1.091	1.061	1.094	1.096	102	95	92	96	96	>1.00E+02	>1.00E+02	>1.00E+02	
	ERXV	0.561	1.345	1.247	1.256	1.237	1.142	1.181	87	89	86	74	79	>1.00E+02	>1.00E+02	>1.00E+02	
	HOP-62	0.163	1.082	1.147	1.156	1.191	1.158	1.109	110	115	114	111	111	>1.00E+02	>1.00E+02	>1.00E+02	
	HOP-92	0.630	0.958	0.717	0.617	0.541	0.551	0.564	26	-2	-14	-13	-10	<1.00E+00	0.92E+00	>1.00E+02	
	MCF-H226	0.269	0.702	0.660	0.588	0.531	0.541	0.539	90	74	61	63	62	>1.00E+02	>1.00E+02	>1.00E+02	
	MCF-H23	0.602	0.657	1.581	1.525	1.463	1.512	1.540	93	88	82	86	89	>1.00E+02	>1.00E+02	>1.00E+02	
	MCF-H322H	0.488	1.265	1.222	1.265	1.256	1.276	1.231	94	100	99	101	93	>1.00E+02	>1.00E+02	>1.00E+02	
	MCF-H460	0.362	1.677	0.416	0.305	0.244	0.256	0.237	4	-16	-33	-29	-33	<1.00E+00	1.27E+00	>1.00E+02	
	MCF-H522	0.374	0.954	0.868	0.830	0.804	0.828	0.839	85	79	74	78	80	>1.00E+02	>1.00E+02	>1.00E+02	
	COLO 205	0.145	0.829	0.003	-0.002	-0.008	0.004	0.009	-98	-100	-98	-94	-94	<1.00E+00	<1.00E+00	<1.00E+00	
Colon Cancer	HCC-T398	0.334	0.797	0.511	0.323	0.246	0.250	0.252	38	4	-26	-25	-25	<1.00E+00	0.370E+00	>1.00E+02	
	HCT-116	0.385	0.058	1.341	1.051	1.008	0.926	0.904	57	40	37	32	31	1.61E+00	>1.00E+02	>1.00E+02	
	HCT-15	0.205	1.218	0.324	0.204	0.146	0.154	0.169	12	0	-29	-25	-18	<1.00E+00	0.33E+00	>1.00E+02	
	H729	0.322	1.464	1.547	1.523	1.566	1.553	1.485	107	105	109	108	102	>1.00E+02	>1.00E+02	>1.00E+02	
	K512	0.240	1.281	1.243	1.218	1.224	1.096	1.097	96	94	95	82	82	>1.00E+02	>1.00E+02	>1.00E+02	
	SK-620	0.134	0.961	0.713	0.721	0.678	0.645	0.594	70	71	66	62	56	>1.00E+02	>1.00E+02	>1.00E+02	
	CNS Cancer	SP-268	0.360	1.045	1.005	1.008	0.992	1.013	0.970	94	94	92	95	89	>1.00E+02	>1.00E+02	>1.00E+02
	SP-295	0.512	1.311	0.344	0.313	0.312	0.313	0.282	-33	-39	-39	-39	-45	8.14E+00	<1.00E+02	>1.00E+02	
	SP-539	0.220	1.153	0.860	0.750	0.673	0.674	0.657	69	57	49	49	47	>1.00E+02	>1.00E+02	>1.00E+02	
	SNB-19	0.316	1.233	1.139	1.143	1.121	1.136	1.157	102	102	100	102	104	>1.00E+02	>1.00E+02	>1.00E+02	
Melanoma	SK-MEL-2	0.345	1.033	0.853	0.835	0.768	0.729	0.668	74	71	61	56	47	6.76E+01	>1.00E+02	>1.00E+02	
	SK-MEL-28	0.346	2.111	1.937	1.893	1.770	1.869	1.721	90	88	81	86	78	>1.00E+02	>1.00E+02	>1.00E+02	
	SK-MEL-5	0.346	2.111	1.937	1.893	1.770	1.869	1.721	90	88	81	86	78	>1.00E+02	>1.00E+02	>1.00E+02	
	UACC-257	0.612	1.307	1.211	1.133	1.062	1.053	0.976	86	75	65	63	35	>1.00E+02	>1.00E+02	>1.00E+02	
	UACC-62	0.597	1.806	1.509	1.338	1.166	1.038	1.024	75	60	47	36	35	>1.00E+02	>1.00E+02	>1.00E+02	
	LAX T47D	0.349	1.703	1.589	1.510	1.366	1.321	1.299	92	86	75	72	70	>1.00E+02	>1.00E+02	>1.00E+02	
	LAX T47D	0.350	0.732	0.643	0.600	0.555	0.557	0.553	77	65	53	54	53	>1.00E+02	>1.00E+02	>1.00E+02	
	MALME-3H	0.320	1.246	0.982	0.783	0.716	0.689	0.703	72	50	43	40	41	1.16E+00	>1.00E+02	>1.00E+02	
	M14	0.592	0.982	0.758	0.712	0.639	0.618	0.622	43	31	12	7	8	<1.00E+00	>1.00E+02	>1.00E+02	
	SK-MEL-2	0.345	1.033	0.853	0.835	0.768	0.729	0.668	74	71	61	56	47	6.76E+01	>1.00E+02	>1.00E+02	
Ovarian Cancer	IGROV1	0.209	0.934	0.927	0.876	0.915	0.905	0.893	99	92	97	96	94	>1.00E+02	>1.00E+02	>1.00E+02	
	OVCA9-3	0.434	1.295	0.566	0.526	0.460	0.439	0.431	15	11	3	1	-1	<1.00E+00	5.19E+01	>1.00E+02	
	OVCA9-4	0.359	1.495	1.464	1.453	1.442	1.404	1.361	97	96	95	92	88	>1.00E+02	>1.00E+02	>1.00E+02	
	OVCA9-8	0.238	0.890	0.903	0.875	0.881	0.923	0.882	102	98	99	105	109	>1.00E+02	>1.00E+02	>1.00E+02	
	SK-OV-3	0.450	1.051	1.051	1.061	1.034	1.068	1.075	100	102	97	103	104	>1.00E+02	>1.00E+02	>1.00E+02	
	Renal Cancer	786-0	0.453	1.495	1.504	1.506	1.492	1.491	1.512	101	101	100	100	102	>1.00E+02	>1.00E+02	>1.00E+02
	A498	0.757	1.482	1.150	0.968	0.743	0.690	0.726	54	79	-2	-9	-4	1.21E+00	9.13E+00	>1.00E+02	
	ACHN	0.292	1.410	1.326	1.231	1.151	1.071	1.062	92	72	44	42	42	>1.00E+02	>1.00E+02	>1.00E+02	
	CAXI-1	0.546	1.151	1.107	1.203	1.149	1.156	1.157	93	109	100	101	101	>1.00E+02	>1.00E+02	>1.00E+02	
	BTX 393	0.511	1.145	0.962	0.839	0.755	0.730	0.788	71	52	39	34	44	3.70E+00	>1.00E+02	>1.00E+02	
Prostate Cancer	SN2C	0.261	1.249	1.055	0.992	0.858	0.843	0.783	92	90	75	77	73	>1.00E+02	>1.00E+02	>1.00E+02	
	TR-10	0.539	1.127	1.116	1.095	1.021	1.028	0.999	98	95	82	83	78	>1.00E+02	>1.00E+02	>1.00E+02	
	VO-31	0.580	1.330	1.391	1.351	1.319	1.301	1.294	108	103	99	96	95	>1.00E+02	>1.00E+02	>1.00E+02	
	PC-3	0.332	0.865	0.653	0.628	0.546	0.545	0.552	60	55	40	40	41	4.75E+00	>1.00E+02	>1.00E+02	
	DU-145	0.336	1.174	1.139	1.134	1.135	1.112	1.112	90	91	85	85	83	>1.00E+02	>1.00E+02	>1.00E+02	
	Breast Cancer	MDA-MB-231/ATCC	0.361	1.913	1.881	1.935	1.827	1.950	2.020	98	101	94	102	107	>1.00E+02	>1.00E+02	>1.00E+02
	MDA-MB-435	0.261	1.249	1.055	0.992	0.858	0.843	0.783	92	90	75	77	73	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-N	0.217	0.971	0.910	0.895	0.782	0.785	0.766	76	48	23	23	18	2.90E+00	>1.00E+02	>1.00E+02	
	BT-549	0.570	1.426	1.237	0.989	0.820	0.773	0.728	93	98	101	103	103	>1.00E+02	>1.00E+02	>1.00E+02	
	T-47D	0.382	1.004	0.963	0.993	1.010	1.013	1.026	93	98	101	103	103	>1.00E+02	>1.00E+02	>1.00E+02	

Fig. 20 B

APO2L - 2 day

Panel/Cell Line	Time Zero	Ctrl	Log10 Concentration					Percent Growth					GI50	TGI	LC50	
			Mean Optical Densities					Percent Growth								
			0.5	1.0	1.5	2.0	0.5	1.0	1.5	2.0						
Leukemia	CCRF-CED	0.081	0.576	0.400	0.510	0.443	0.447	0.476	64	87	73	74	80	>1.00E+02	>1.00E+02	>1.00E+02
	HL-60(TB)	0.487	1.926	1.660	1.118	1.074	0.881	0.957	82	44	41	27	26	2.63E+00	>1.00E+02	>1.00E+02
	K-562	0.238	1.596	1.629	1.557	1.416	1.371	1.349	102	97	87	83	82	>1.00E+02	>1.00E+02	>1.00E+02
	MOLT-4	0.215	1.126	1.132	1.131	1.136	1.136	1.167	101	101	101	101	104	>1.00E+02	>1.00E+02	>1.00E+02
	RPMI-8226	0.335	1.284	0.599	0.427	0.348	0.359	0.345	28	10	1	2	1	<1.00E+00	>1.00E+02	>1.00E+02
	SR	0.279	1.820	1.578	1.475	1.417	1.428	1.460	84	78	74	75	77	>1.00E+02	>1.00E+02	>1.00E+02
	Non-Small Cell Lung Cancer															
	A549/ATCC	0.212	1.164	1.177	1.173	1.086	1.052	1.068	101	101	92	88	90	>1.00E+02	>1.00E+02	>1.00E+02
	EXVX	0.561	1.328	1.325	1.337	1.228	1.275	1.266	100	101	87	93	92	>1.00E+02	>1.00E+02	>1.00E+02
	HOP-62	0.363	1.260	1.241	1.174	1.106	1.202	1.126	98	90	83	94	86	>1.00E+02	>1.00E+02	>1.00E+02
Colon Cancer																
COLO 205	0.145	0.814	0.029	0.025	0.015	0.021	0.021	-80	-83	-90	-86	-86	<1.00E+00	<1.00E+00	<1.00E+00	
HCT-2998	0.334	0.742	0.538	0.354	0.291	0.260	0.235	50	5	-13	-22	-30	<1.00E+00	4.34E+00	>1.00E+02	
HCT-116	0.385	1.855	0.726	0.483	0.389	0.348	0.349	23	7	0	-10	-9	<1.00E+00	1.03E+01	>1.00E+02	
HCT-15	0.205	1.183	0.279	0.211	0.144	0.128	0.125	8	1	-30	-38	-39	<1.00E+00	3.24E+00	>1.00E+02	
Ht29	0.322	1.477	1.515	1.485	1.404	1.462	1.446	103	101	94	99	97	>1.00E+02	>1.00E+02	>1.00E+02	
KM12	0.240	1.440	1.235	1.190	0.922	0.865	0.799	83	79	57	52	47	>1.00E+02	>1.00E+02	>1.00E+02	
SW-620	0.134	0.962	0.849	0.744	0.674	0.632	0.607	86	74	65	60	57	>1.00E+02	>1.00E+02	>1.00E+02	
CNS Cancer																
SF-268	0.360	0.874	0.891	0.873	0.886	0.901	0.898	103	100	102	105	105	>1.00E+02	>1.00E+02	>1.00E+02	
SF-295	0.512	1.273	0.862	0.728	0.636	0.670	0.603	46	28	16	21	12	>1.00E+02	>1.00E+02	>1.00E+02	
SF-539	0.220	1.040	1.006	0.820	0.632	0.528	0.574	96	73	50	38	43	>1.00E+02	>1.00E+02	>1.00E+02	
SNB-19	0.316	1.144	1.164	1.172	1.151	1.194	1.121	102	103	101	106	106	>1.00E+02	>1.00E+02	>1.00E+02	
SNB-75	0.326	0.663	0.623	0.637	0.618	0.663	0.589	88	92	87	91	78	>1.00E+02	>1.00E+02	>1.00E+02	
U751	0.197	0.980	0.913	0.909	0.814	0.833	0.876	91	91	79	81	87	>1.00E+02	>1.00E+02	>1.00E+02	
Melanoma																
LOX IMVI	0.349	1.657	1.606	1.494	1.415	1.380	1.464	96	88	81	79	85	>1.00E+02	>1.00E+02	>1.00E+02	
MALME-3H	0.350	0.690	0.710	0.701	0.663	0.671	0.647	106	103	92	94	87	>1.00E+02	>1.00E+02	>1.00E+02	
M14	0.320	1.267	1.213	1.130	1.167	1.124	1.104	94	85	89	85	83	>1.00E+02	>1.00E+02	>1.00E+02	
SK-MEL-2	0.592	1.003	0.879	0.929	0.920	0.905	0.954	70	82	80	76	88	>1.00E+02	>1.00E+02	>1.00E+02	
SK-MEL-28	0.345	1.061	1.051	1.028	0.986	0.991	0.930	99	95	89	90	82	>1.00E+02	>1.00E+02	>1.00E+02	
SK-MEL-5	0.346	2.127	2.076	2.082	2.081	2.217	2.042	97	98	97	105	95	>1.00E+02	>1.00E+02	>1.00E+02	
UACC-257	0.612	1.245	1.289	1.256	1.199	1.189	1.113	107	102	93	91	79	>1.00E+02	>1.00E+02	>1.00E+02	
UACC-62	0.597	2.056	1.844	1.677	1.650	1.675	1.582	85	74	72	74	68	>1.00E+02	>1.00E+02	>1.00E+02	
Ovarian Cancer																
IGROVI	0.209	0.916	0.947	0.982	0.912	0.960	0.973	104	109	99	106	108	>1.00E+02	>1.00E+02	>1.00E+02	
OVCAR-3	0.434	1.456	0.983	0.787	0.765	0.658	0.651	54	34	32	22	21	>1.00E+02	>1.00E+02	>1.00E+02	
OVCAR-4	0.359	1.518	1.472	1.477	1.274	1.310	1.180	96	96	79	82	71	>1.00E+02	>1.00E+02	>1.00E+02	
OVCAR-5	1.107	1.815	1.700	1.618	1.446	1.452	1.493	84	72	48	49	54	>1.00E+02	>1.00E+02	>1.00E+02	
OVCAR-8	0.238	0.927	0.928	0.938	0.896	0.930	0.950	100	102	95	100	103	>1.00E+02	>1.00E+02	>1.00E+02	
SK-OV-3	0.450	1.167	1.126	1.123	1.077	1.162	1.175	94	94	87	99	101	>1.00E+02	>1.00E+02	>1.00E+02	
Renal Cancer																
786-0	0.453	1.424	1.386	1.400	1.434	1.446	1.489	96	98	101	102	107	>1.00E+02	>1.00E+02	>1.00E+02	
A498	0.757	1.493	1.293	0.950	0.768	0.606	0.616	73	26	1	-20	-19	>1.00E+02	>1.00E+02	>1.00E+02	
ACHN	0.360	1.548	1.526	1.590	1.527	1.363	1.318	98	104	81	84	81	>1.00E+02	>1.00E+02	>1.00E+02	
CAXI-1	0.292	1.503	1.439	1.477	1.266	1.371	1.210	95	98	80	89	76	>1.00E+02	>1.00E+02	>1.00E+02	
RFX 393	0.546	1.208	1.172	1.170	1.087	1.086	1.058	95	94	82	82	77	>1.00E+02	>1.00E+02	>1.00E+02	
SN12C	0.511	1.155	1.055	1.072	1.050	1.080	1.064	85	87	84	88	86	>1.00E+02	>1.00E+02	>1.00E+02	
TK-10	0.539	1.080	1.060	0.975	0.939	0.839	0.756	96	81	74	56	40	>1.00E+02	>1.00E+02	>1.00E+02	
UO-31	0.580	1.342	1.334	1.361	1.391	1.387	1.439	99	102	106	106	113	>1.00E+02	>1.00E+02	>1.00E+02	
Prostate Cancer																
PC-3	0.332	0.886	0.758	0.746	0.700	0.684	0.692	77	75	66	64	65	>1.00E+02	>1.00E+02	>1.00E+02	
DU-145	0.336	1.314	1.249	1.215	1.052	0.842	0.766	93	90	73	52	44	>1.00E+02	>1.00E+02	>1.00E+02	
Breast Cancer																
MDA-MB-231/ATCC	0.361	2.217	1.918	1.618	1.333	1.279	1.180	84	68	52	49	44	>1.00E+02	>1.00E+02	>1.00E+02	
MDA-MB-435	0.217	1.392	1.295	1.274	1.027	1.055	1.047	91	90	68	70	61	>1.00E+02	>1.00E+02	>1.00E+02	
MDA-N	0.261	0.929	0.859	0.897	0.806	0.807	0.807	90	96	83	83	83	>1.00E+02	>1.00E+02	>1.00E+02	
BT-549	0.570	1.415	1.383	1.377	1.294	1.256	1.266	96	96	86	86	81	>1.00E+02	>1.00E+02	>1.00E+02	
T-47D	0.382	1.044	1.014	1.025	1.000	1.054	0.955	95	97	93	101	87	>1.00E+02	>1.00E+02	>1.00E+02	

Fig. 21 A

16E2 Octopus (anti-DR5) - 6 day


Panel/Cell Line	Time Zero	Ctrl	Mean Optical Densities				Log10 Concentration				Percent Growth				G150	TGI	LC50
			0.5	1.0	1.5	2.0	0.5	1.0	1.5	2.0	0.5	1.0	1.5	2.0			
Leukemia	CCRF-CEM	0.004	0.731	0.832	0.730	0.789	0.720	0.103	114	100	108	98	14	6.11E+01	>1.00E+02	>1.00E+02	>1.00E+02
	HL-60(TB)	0.068	2.840	2.914	2.950	2.924	2.813	2.039	103	104	103	99	71	>1.00E+02	>1.00E+02	>1.00E+02	
	K-562	0.046	2.941	2.912	2.718	2.776	2.799	2.688	99	94	93	91	71	>1.00E+02	>1.00E+02	>1.00E+02	
	MOLT-4	0.009	0.981	0.450	0.287	0.266	0.282	0.196	45	29	26	28	19	<1.00E+00	>1.00E+02	>1.00E+02	
	RPMI-8226	0.061	1.637	0.904	0.725	0.604	0.584	0.618	53	42	34	33	35	1.43E+00	>1.00E+02	>1.00E+02	
	SR	0.031	2.631	0.642	0.261	0.136	0.091	0.110	24	9	4	2	3	<1.00E+00	>1.00E+02	>1.00E+02	
Non-Small Cell Lung Cancer	A549/ATCC	0.021	2.721	2.734	2.443	2.524	2.458	2.314	100	90	93	90	85	>1.00E+02	>1.00E+02	>1.00E+02	
	ERXV	0.057	1.201	0.939	0.896	0.773	0.683	0.581	77	73	63	55	46	5.80E+01	>1.00E+02	>1.00E+02	
	HOP-62	0.059	0.922	0.750	0.767	0.683	0.595	0.541	80	82	72	62	56	>1.00E+02	>1.00E+02	>1.00E+02	
	HOP-92	0.110	0.792	0.642	0.573	0.577	0.525	0.512	78	68	68	61	59	>1.00E+02	>1.00E+02	>1.00E+02	
	NCI-H23	0.103	1.191	1.103	1.027	1.069	1.034	1.057	92	85	89	86	88	>1.00E+02	>1.00E+02	>1.00E+02	
	NCI-H322H	0.038	1.051	0.841	0.716	0.858	0.965	0.826	79	67	81	92	78	>1.00E+02	>1.00E+02	>1.00E+02	
Colon Cancer	NCI-H460	0.050	2.780	1.042	0.668	0.399	0.459	0.387	36	23	13	15	12	<1.00E+00	>1.00E+02	>1.00E+02	
	NCI-H522	0.064	0.648	0.481	0.406	0.386	0.409	0.307	71	59	55	59	42	5.77E+01	>1.00E+02	>1.00E+02	
	COLO 205	0.001	1.430	-0.014	-0.033	-0.014	-0.014	-0.013	-100	-100	-100	-100	-100	<1.00E+00	<1.00E+00	<1.00E+00	
	HCC-2998	0.031	0.974	0.296	0.096	0.067	0.047	0.036	28	7	4	2	1	<1.00E+00	>1.00E+02	>1.00E+02	
	HCT-116	0.068	2.951	2.404	2.329	2.028	1.901	1.691	81	78	68	64	56	>1.00E+02	>1.00E+02	>1.00E+02	
	HCT-15	0.020	2.056	0.435	0.168	0.100	0.096	0.107	20	7	4	4	4	<1.00E+00	>1.00E+02	>1.00E+02	
CNS Cancer	HT29	0.052	2.528	2.445	2.325	2.293	2.387	2.210	97	92	91	94	87	>1.00E+02	>1.00E+02	>1.00E+02	
	KM12	0.010	0.708	0.390	0.334	0.486	0.290	0.283	54	46	68	40	39	>1.00E+02	>1.00E+02	>1.00E+02	
	SW-620	0.010	2.141	1.392	1.302	1.282	1.145	0.966	65	61	60	53	45	4.95E+01	>1.00E+02	>1.00E+02	
	SP-268	0.041	1.069	1.017	0.969	0.993	0.980	0.958	95	90	93	91	89	>1.00E+02	>1.00E+02	>1.00E+02	
	SP-295	0.054	1.614	0.031	0.019	0.018	0.023	0.023	-43	-66	-67	-57	-57	<1.00E+00	>1.00E+02	>1.00E+02	
	SP-539	0.030	1.468	0.875	0.672	0.624	0.616	0.572	59	45	41	43	38	2.05E+00	>1.00E+02	>1.00E+02	
Melanoma	SK-MEL-28	0.045	1.813	1.594	1.598	1.544	1.794	1.822	88	88	85	99	100	>1.00E+02	>1.00E+02	>1.00E+02	
	SK-MEL-5	0.095	1.885	1.902	1.947	1.880	1.916	1.895	101	103	100	102	101	>1.00E+02	>1.00E+02	>1.00E+02	
	UACC-257	0.063	0.524	0.534	0.477	0.485	0.541	0.530	102	90	91	104	101	>1.00E+02	>1.00E+02	>1.00E+02	
	UACC-62	0.012	1.561	0.188	0.163	0.116	0.166	0.147	11	10	7	10	9	<1.00E+00	>1.00E+02	>1.00E+02	
	LOX IMVI	0.037	3.073	2.094	1.635	1.272	1.229	1.274	68	53	41	39	41	4.08E+00	>1.00E+02	>1.00E+02	
	M14	0.035	1.838	1.147	0.745	0.628	0.585	0.652	62	39	33	31	34	1.83E+00	>1.00E+02	>1.00E+02	
Ovarian Cancer	SK-OV-3	0.083	0.498	0.209	0.160	0.166	0.151	0.153	30	19	20	16	17	<1.00E+00	>1.00E+02	>1.00E+02	
	OVCA9-4	0.071	1.563	1.304	1.287	1.028	0.998	0.854	83	81	64	62	52	>1.00E+02	>1.00E+02	>1.00E+02	
	OVCA9-5	0.101	1.606	1.390	1.053	1.046	0.873	0.837	86	63	63	51	49	5.85E+01	>1.00E+02	>1.00E+02	
	OVCA9-8	0.020	1.565	1.634	1.571	1.587	1.630	1.570	104	100	101	104	100	>1.00E+02	>1.00E+02	>1.00E+02	
	SK-OV-3	0.056	0.811	0.817	0.812	0.813	0.759	0.769	101	100	100	93	94	>1.00E+02	>1.00E+02	>1.00E+02	
	IGROV1	0.018	1.567	1.476	1.603	1.622	1.529	1.510	94	102	104	98	96	>1.00E+02	>1.00E+02	>1.00E+02	
Renal Cancer	OVCA9-3	0.086	1.285	0.039	0.041	0.039	0.040	0.033	-55	-52	-55	-53	-62	<1.00E+00	<1.00E+00	<1.00E+00	
	ACHN	0.041	1.970	1.331	0.307	0.016	0.020	0.020	67	14	-61	-51	-51	1.44E+00	3.92E+00	8.46E+00	
	CAXI-1	0.033	1.215	0.797	0.758	0.492	0.535	0.512	65	61	39	42	41	5.66E+00	>1.00E+02	>1.00E+02	
	RFX 393	0.101	0.973	0.496	0.086	0.043	0.029	0.028	45	-15	-58	-71	-72	<1.00E+00	2.37E+00	8.08E+00	
	SN12C	0.054	1.263	0.669	0.504	0.358	0.315	0.249	51	37	25	22	16	1.08E+00	>1.00E+02	>1.00E+02	
	TK-10	0.057	1.064	1.000	0.925	0.811	0.666	0.568	94	86	75	60	51	>1.00E+02	>1.00E+02	>1.00E+02	
Prostate Cancer	UO-31	0.095	1.457	1.201	0.838	0.701	0.476	0.418	81	55	44	28	24	5.32E+00	>1.00E+02	>1.00E+02	
	786-0	0.073	1.715	1.716	1.715	1.726	1.731	1.686	100	100	101	101	98	>1.00E+02	>1.00E+02	>1.00E+02	
	A498	0.087	1.058	0.996	0.877	0.737	0.692	0.716	94	81	67	62	65	>1.00E+02	>1.00E+02	>1.00E+02	
	PC-3	0.030	0.879	0.520	0.379	0.334	0.315	0.333	58	41	36	34	36	1.70E+00	>1.00E+02	>1.00E+02	
	DU-145	0.057	1.962	1.887	1.790	1.717	1.662	1.654	96	91	87	84	84	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-231/ATCC	0.045	1.087	1.064	1.054	1.157	1.130	1.088	98	97	104	100	98	>1.00E+02	>1.00E+02	>1.00E+02	
Breast Cancer	NCI-MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-231/ATCC	0.045	1.087	1.064	1.054	1.157	1.130	1.088	98	97	104	100	98	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
Breast Cancer	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
Breast Cancer	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
Breast Cancer	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	
Breast Cancer	MDA-MB-435	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>	

Figure 21B shows the results of the APO2L - 6 day assay. The data is presented in a table format, showing the mean optical densities (OD) and percent growth for various cell lines and treatments. The table is organized into columns for Time, Panel/Cell Line, Zero, Ctrl1, Mean Optical Densities (0.5, 1.0, 1.5, 2.0), Percent Growth (0.5, 1.0, 1.5, 2.0), and Log10 Concentration (0.5, 1.0, 1.5, 2.0). The cell lines are grouped into Leukemia, Non-Small Cell Lung Cancer, Colon Cancer, CNS Cancer, Melanoma, Ovarian Cancer, Renal Cancer, and Prostate Cancer. The treatments are categorized by Log10 Concentration (0.5, 1.0, 1.5, 2.0) and Percent Growth (0.5, 1.0, 1.5, 2.0). The data shows that the APO2L treatment significantly reduces the growth of various cell lines, particularly at higher concentrations and longer treatment times.






APO2L - 6 day

Panel/Cell Line	Time Zero	Ctrl	Mean Optical Densities				Percent Growth				GI50	TCI	LC50		
			0.5	1.0	1.5	2.0	0.5	1.0	1.5	2.0					
Leukemia	CCR5-CEM	0.004	0.842	0.753	0.453	0.365	0.574	0.569	89	54	43	68	67	>1.00E+02	>1.00E+02
	HL-60(TB)	0.068	2.822	0.712	0.317	0.202	0.116	0.080	23	9	5	2	0	<1.00E+00	>1.00E+02
	F-562	0.046	2.792	2.962	3.017	2.920	2.716	2.626	106	108	105	97	94	>1.00E+02	>1.00E+02
	MOLT-4	0.009	1.040	0.929	0.928	0.965	0.999	0.797	89	89	93	96	76	>1.00E+02	>1.00E+02
	RPMT-8226	0.061	1.661	0.072	0.038	0.041	0.025	0.022	1	-39	-34	-59	-65	<1.00E+00	1.03E+00 2.10E+01
	SR	0.031	2.591	2.540	2.234	1.915	1.822	1.708	98	86	74	70	65	>1.00E+02	>1.00E+02
Non-Small Cell Lung Cancer	NCI-H549/ATCC	0.021	2.037	2.071	2.070	2.029	2.045	2.038	102	102	100	100	100	>1.00E+02	>1.00E+02
	EXVX	0.057	1.052	1.070	1.039	1.078	1.000	0.962	102	99	103	95	91	>1.00E+02	>1.00E+02
	HOP-62	0.039	0.891	0.854	0.854	0.787	0.725	0.662	96	95	87	80	72	>1.00E+02	>1.00E+02
	HOP-92	0.110	0.906	0.750	0.698	0.700	0.705	0.723	80	74	74	75	77	>1.00E+02	>1.00E+02
	NCI-H23	0.103	1.184	1.180	1.147	1.122	1.185	1.163	100	97	94	100	98	>1.00E+02	>1.00E+02
	NCI-H322H	0.038	0.976	0.824	0.606	0.488	0.436	0.346	84	60	48	42	33	8.30E+00	>1.00E+02
Colon Cancer	NCI-H460	0.050	2.857	0.536	0.239	0.153	0.063	0.048	17	7	4	0	-4	<1.00E+00	3.57E+01 >1.00E+02
	NCI-H522	0.064	0.461	0.354	0.344	0.336	0.263	0.238	73	70	68	50	44	3.22E+01	>1.00E+02 >1.00E+02
	COLO 205	0.001	1.396	-0.005	-0.007	0.006	0.002	0.014	-100	-100	0	0	1	<1.00E+00	>1.00E+02
	HCC-2998	0.031	1.083	0.682	0.274	0.305	0.202	0.189	62	23	26	16	15	1.43E+00	>1.00E+02 >1.00E+02
	HCT-116	0.068	3.014	2.272	1.606	1.249	0.953	0.821	75	52	40	30	26	3.91E+00	>1.00E+02 >1.00E+02
	HCT-15	0.020	2.169	0.196	0.054	0.039	0.018	0.030	8	2	1	-10	0	<1.00E+00	>1.00E+02
CNS Cancer	HT29	0.052	1.968	1.970	1.962	2.035	2.034	2.063	100	100	103	105	100	>1.00E+02	>1.00E+02
	SK-N-SH	0.010	0.633	0.249	0.218	0.133	0.052	0.052	38	33	20	7	7	<1.00E+00	>1.00E+02 >1.00E+02
	SK-N-BE	0.010	0.633	0.249	0.218	0.133	0.052	0.052	38	33	20	7	7	<1.00E+00	>1.00E+02 >1.00E+02
	SK-N-SH	0.010	0.633	0.249	0.218	0.133	0.052	0.052	38	33	20	7	7	<1.00E+00	>1.00E+02 >1.00E+02
	SK-N-SH	0.010	0.633	0.249	0.218	0.133	0.052	0.052	38	33	20	7	7	<1.00E+00	>1.00E+02 >1.00E+02
	SK-N-SH	0.010	0.633	0.249	0.218	0.133	0.052	0.052	38	33	20	7	7	<1.00E+00	>1.00E+02 >1.00E+02
Melanoma	LOX IMVI	0.037	3.184	2.701	2.366	2.418	2.050	2.276	85	74	76	64	71	>1.00E+02	>1.00E+02
	M14	0.035	1.827	1.721	1.740	1.634	1.636	1.551	94	95	89	89	85	>1.00E+02	>1.00E+02
	SK-MEL-2	0.083	0.504	0.366	0.344	0.393	0.383	0.391	67	62	73	71	73	>1.00E+02	>1.00E+02
	SK-MEL-28	0.045	1.350	1.130	1.163	1.105	0.843	0.843	83	86	81	74	61	>1.00E+02	>1.00E+02
	SK-MEL-5	0.095	1.718	1.748	1.792	1.711	1.824	2.003	102	105	100	107	118	>1.00E+02	>1.00E+02
	UACC-257	0.070	0.830	0.756	0.716	0.744	0.692	0.664	90	85	89	82	78	>1.00E+02	>1.00E+02
Ovarian Cancer	UACC-62	0.121	1.729	1.649	1.630	1.410	1.396	1.459	95	94	80	79	83	>1.00E+02	>1.00E+02
	IGROV1	0.018	1.901	1.898	1.794	1.820	1.801	1.734	100	94	96	95	91	>1.00E+02	>1.00E+02
	OVCAR-3	0.086	1.293	0.997	0.973	0.949	0.932	0.937	1	-16	-43	-63	-57	<1.00E+00	1.07E+00 1.50E+01
	OVCAR-4	0.071	1.553	1.364	1.289	1.245	1.060	1.102	87	82	79	67	70	>1.00E+02	>1.00E+02
	OVCAR-5	0.101	1.436	1.357	1.269	1.246	1.206	1.149	94	87	86	83	78	>1.00E+02	>1.00E+02
	OVCAR-8	0.020	1.641	1.540	1.606	1.595	1.634	1.608	94	98	97	100	98	>1.00E+02	>1.00E+02
Renal Cancer	SK-OV-3	0.056	0.848	0.834	0.807	0.853	0.821	0.834	98	95	101	97	98	>1.00E+02	>1.00E+02
	786-0	0.073	1.816	1.818	1.830	1.853	1.816	1.834	100	101	102	100	101	>1.00E+02	>1.00E+02
	A498	0.087	1.108	1.080	1.046	1.034	0.988	0.969	97	94	93	88	86	>1.00E+02	>1.00E+02
	ACHN	0.041	2.105	2.060	2.051	1.993	1.958	1.867	98	97	95	93	88	>1.00E+02	>1.00E+02
	CAXI-1	0.033	1.080	1.108	0.941	1.017	1.031	0.959	103	87	94	95	88	>1.00E+02	>1.00E+02
	RFX 393	0.101	0.982	0.589	0.322	0.362	0.450	0.262	55	25	30	40	18	1.23E+00	>1.00E+02
Prostate Cancer	SN12C	0.054	1.352	1.354	1.353	1.319	1.346	1.257	100	100	97	100	93	>1.00E+02	>1.00E+02
	TX-10	0.057	1.226	1.159	1.058	1.042	0.939	0.802	94	86	84	75	64	>1.00E+02	>1.00E+02
	UP-31	0.095	1.523	1.434	1.395	1.377	1.343	1.340	94	91	90	87	87	>1.00E+02	>1.00E+02
	PC-3	0.030	0.817	0.520	0.467	0.384	0.426	0.342	62	56	45	50	40	>1.00E+02	>1.00E+02
	DJ-145	0.057	1.911	1.810	1.744	1.693	1.624	1.624	95	91	88	70	52	>1.00E+02	>1.00E+02
	MDA-MB-231/ATCC	0.042	0.873	0.774	0.755	0.805	0.750	0.720	88	86	92	85	82	>1.00E+02	>1.00E+02
Breast Cancer	MDA-MB-435	0.055	0.481	0.512	0.511	0.508	0.518	0.515	105	105	104	106	106	>1.00E+02	>1.00E+02
	MDA-N	0.010	0.984	0.809	0.738	0.603	0.677	0.571	82	75	81	68	58	>1.00E+02	>1.00E+02
	BT-549	0.100	1.296	1.457	1.398	1.377	1.346	1.346	113	109	107	111	104	>1.00E+02	>1.00E+02
	T-47D	0.049	0.567	0.582	0.568	0.595	0.566	0.490	103	100	105	100	100	>1.00E+02	>1.00E+02
	MDA-MB-231/ATCC	0.042	0.873	0.774	0.755	0.805	0.750	0.720	88	86	92	85	82	>1.00E+02	>1.00E+02
	MDA-MB-435	0.055	0.481	0.512	0.511	0.508	0.518	0.515	105	105	104	106	106	>1.00E+02	>1.00E+02
Breast Cancer	MDA-N	0.010	0.984	0.809	0.738	0.603	0.677	0.571	82	75	81	68	58	>1.00E+02	>1.00E+02
	BT-549	0.100	1.296	1.457	1.398	1.377	1.346	1.346	113	109	107	111	104	>1.00E+02	>1.00E+02
	T-47D	0.049	0.567	0.582	0.568	0.595	0.566	0.490	103	100	105	100	100	>1.00E+02	>1.00E+02
	MDA-MB-231/ATCC	0.042	0.873	0.774	0.755	0.805	0.750	0.720	88	86	92	85	82	>1.00E+02	>1.00E+02
	MDA-MB-435	0.055	0.481	0.512	0.511	0.508	0.518	0.515	105	105	104	106	106	>1.00E+02	>1.00E+02
	MDA-N	0.010	0.984	0.809	0.738	0.603	0.677	0.571	82	75	81	68	58	>1.00E+02	>1.00E+02

Fig. 22



Size comparison of Octopus Constructs:






Fig. 24




Fig. 25





Fig. 26



Representative plot of $n = 6$ cytotoxicity assays; crystal violet

Fig. 27




Fig. 28A




Fig. 28B

OctHER2..... POPoct-3HER2——

○● Unbound □■ Cell surface bound ▲△ Intracellular ◇◇ Catabolized




Fig. 29A

Fig. 29B




Fig. 30A




Fig. 30B

$n = 4$ apoptosis assays
Crystal violet

Fig. 31A




Fig. 31B




Fig. 32




Fig. 33





Fig. 34






Fig. 35